<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-nebivolol.xml</id>
  <title>Recalls Watch: Nebivolol</title>
  <link rel="self" href="https://recalls.watch/feed/substance-nebivolol.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2025-12-17T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/98014/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Nebivolol Tablets</title>
    <link href="https://recalls.watch/recall/fda/98014/"/>
    <updated>2025-12-17T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Cross Contamination with Other Products</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95934/</id>
    <title>Aurobindo Pharma USA Inc: Nebivolol Tablets</title>
    <link href="https://recalls.watch/recall/fda/95934/"/>
    <updated>2024-12-25T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.</summary>
  </entry>
</feed>
